SEC Form 4 · accession 0001013606-17-000018
ENDOLOGIX INC /DE/ · ELGX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D McDermott
Officer — Chief Executive Officer · Director
Period of report
Feb 7, 2017
Accepted (ET)
Feb 9, 2017 · 3:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001013606
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 7, 2017 | A | 106,242 | $0.00 | A | 646,920 | D | |
| Common StockF2 | Feb 7, 2017 | F | 17,276 | $6.94 | D | 629,644 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This award was originally reported on a Form 4 filed with the Securities and Exchange Commission on February 17, 2016. 33% percent of the shares subject to this restricted stock award vested pursuant the terms of this award.
- F2Shares sold on February 7, 2017 to satisfy statutory minimum tax withholding obligations related to shares vested on February 4, 2017.